 (P = .0002; odds ratio, 0.78; 95% CI,
Conclusions: Clinical decision support can help curtail inappropriate plasma use but needs to be part of a comprehensive strategy including audit and feedback for comprehensive, long-term changes.
As health care spending accounts for about a sixth of gross domestic product, the United States has faced significant pressure to curtail what is often described as a highly inefficient care delivery system. The Institute of Medicine estimated in a 2012 report 1 that about 30% of all health care spending is wasteful. The passing of the Affordable Care Act in 2010 was a major attempt to shift US health care economics away from fee for service to fixed payments and reimbursing outcomes. The act placed an efficiency burden on providers and health systems to keep patients healthy and to order only necessary diagnostics and therapeutics. Concomitant with these national changes, the American Board of Internal Medicine in 2012 launched the Choosing Wisely campaign to identify low-value care elements in a number of subspecialties. 2 For transfusion medicine and blood banking, this focus has been on curtailing unnecessary blood transfusion as these products carry risks, are costly, and thus should be conserved for patients who may benefit the most.
Much of the work around appropriate blood product utilization has focused solely on RBC transfusion. Randomized controlled trials [3] [4] [5] [6] and a large Cochrane meta-analysis 7 concluded that most patients have equivalent or better outcomes with a restrictive RBC transfusion practice. At our institution, we have had great success after introducing clinical decision support (CDS) in the form of best practice alerts (BPAs) when providers were ordering RBCs in patients with a recent hemoglobin level of 7 to 8 g/dL or more. [8] [9] [10] A focus on inappropriate plasma transfusion is often lacking as part of blood utilization strategies at many health centers. The decision to transfuse RBCs is complex with clinical factors such as symptomatic anemia and acute blood loss playing a role beyond just the hemoglobin value. With plasma, the decision can often be less complex, but the evidence supporting the majority of plasma transfusion for prophylaxis or to counteract bleeding in mild coagulopathy is lacking. 11, 12 While laboratorians designed the international normalized ratio (INR) to guide warfarin therapy and never intended use as a measure of bleeding risk or coagulopathy, INR values are often clinically used to guide plasma transfusion.
At our institution, we applied CDS to improve utilization and to curtail inappropriate use of plasma that is often based on mildly elevated INR values. We studied both outcomes on plasma usage and provider behavior to the BPA in terms of acceptance vs choosing a clinical exception.
Materials and Methods
The study was conducted under the approval of our institutional review board (IRB). The requirement for written informed consent was waived by the IRB. A blood utilization task force initially met with leaders of various departments, including medicine, surgery, anesthesia, neurosurgery, neurology, radiology, and so on, to review literature and develop local guidelines for appropriate plasma use. We were able to establish a consensus that plasma transfusion should not be provided as prophylaxis for patients with minimally elevated INR from 1.7 to 2.0. Due to concern from many of the procedural area physicians, we were unable to establish a consensus of not transfusing plasma to actively bleeding patients even if INR was only minimally elevated. While other institutions such as Massachusetts General Hospital have used an INR value of 2.0 13 as their threshold to consider transfusion, our local clinical consensus was more conservative, and a value of 1.7 was ultimately chosen as a threshold for use in our decision support too.
Based on the local guidelines, we built a BPA alert ❚Figure 1❚ that triggered to the provider at the time of ordering plasma in our electronic health record (EHR; version 2015; Epic Systems, Verona, WI) if the patient's most recent INR value was 1.7 or less (look-back period 3 days). The alert did not trigger for plasma orders placed as part of massive or emergency release protocols due to different underlying procedure records. The alert was excluded for orders placed in the operative or apheresis settings through department location restrictions built into the BPA. The BPA recommends to not transfuse plasma based on best-practice evidence with a link to relevant literature and automatically removes the plasma order if the provider clicks accepts. As clinical documentation and patient location are often not updated in real time, we built in clinical exceptions within the alert (active bleeding, apheresis, other clinical indication) to allow providers to transfuse as deemed necessary; other clinical indication was added as we could not anticipate all the reasons why a provider may choose to continue transfusion. The alert does allow users to enter comments, but ❚Figure 1❚ Plasma best practice alert (BPA) presented at time of ordering BPA is triggered at time of plasma order if patient's most recent international normalized ratio is 1.7 or less (look-back period 3 days). Alert is suppressed as part of massive transfusion or for orders in operative or apheresis settings. Plasma order is automatically removed if "accept" is clicked, and continuation of the order requires one of three acknowledgment reasons. FFP, fresh-frozen plasma. © 2017 Epic Systems Corporation. Used with permission. these are not required. As the intended intervention was CDS, the primary mass communication occurred through our weekly electronic newsletter to medical staff as part of other announcements. There were small presentations during one to two service line meetings but no feedback or training provided at the individual level.
To study the intervention appropriately, we established a control period for 7 months prior to the alert go-live and 4-month period afterward as our intervention period. Patient volume was measured as patient days that capture both patient admissions and length of stay. Relevant data for each plasma transfusion (most recent INR, provider name and specialty, issue to location) were captured for locations that received the alert (outside of apheresis and operative settings) via the EHR's data storage system. In addition, provider behavior to the alert was studied through data embedded into our local analytics platform. It is important to note that while the CDS did not display in operative settings, it did affect surgically related subservices (anesthesia, general surgery, cardiothoracic surgery) as these faculty are involved in transfusion decisions in the perioperative setting and anesthesia faculty actively manage patients in the intensive care unit (ICU) setting. From historical data, we established that the average percentage of plasma units issued to patients with an INR of 1.7 or less was approximately 50% of 385 units issued per month (unpublished observations). We carried out a power analysis (using G*Power 3.1.9.2, Universität Düsseldorf, Germany) to estimate the number of months of usage data we would need to collect to detect a 5% absolute decrease of inappropriate plasma use (units issued to patients with most recent INR of ≤1.7) at the .05 significance level employing a Fisher exact test. We estimated that a total of 3,585 transfused units were needed to achieve 80% power to detect this difference. This corresponded to approximately 10 months of usage data consistent with our study design.
Following our study period, statistical analysis of plasma usage was performed using a Fisher exact test (GraphPad Software, San Diego, CA). To control for possible differences in patient population before vs after CDS go-live, we compared data for length of stay, age, sex, and case mix index during these two time periods using R statistical software (version 3.3.1, R Foundation for Statistical Computing, Vienna, Austria). These data were collected only from units where the CDS was displayed with the exception of case mix index, which was compared both hospital-wide and in each unit with CDS. Length-of-stay data were analyzed using the "survival" package. A log-rank test was carried out to assess for differences in the survival distribution (length of stay) of patients prior to vs after CDS implementation. The distribution of patient ages was found to deviate from normality by a Shapiro-Wilk test, and therefore these data were analyzed using a Mann-Whitney U test from the "exactRankTests" package to account for potential ties. The ratio of male to female patients was assessed using a difference-in-proportions test (prop.test function). Case mix index data were calculated by month from the entire hospital (hospital-wide) and each unit where the CDS was implemented. These data were compared using Welch's two-sample t test. In each of the 17 units, there were no significant differences in case mix index between the control and intervention period after correcting for false discovery using the Benjamini-Hochberg procedure. The P value reported for the hospital-wide case mix index is unadjusted. This analysis is part of the transfusion medicine program IRB approval for patient clinical research (Stanford University IRB protocol 3124). SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence Guidelines 2.0) method was used by the authors.
Results
The monthly absolute plasma utilization in areas affected by the alert normalized by patient volume decreased from a mean ± SD of 3.40 ± 0.48 to 2.82 ± 0.6 plasma units per hundred patient days (95% confidence interval [CI] of difference, -0.1 to 1.3 units per hundred patient days), a decrease of 17.4% (control period: 3,303 units and 97,400 patient days vs intervention: 1,396 units and 49,835 patient days). The rate of potential inappropriate use measured by amount of plasma units transfused when most recent INR was 1.7 or less decreased from 47.6% to 41.6% (P = .0002; odds ratio [OR], 0.78; 95% CI, 0.69-0.89). This represents a relative decrease of 14.6% in potential inappropriate plasma use ❚Figure 2❚. Over the same period, there was no difference in length of stay (P = .38), hospital-wide case mix index (P = .1024), or sex makeup (P = .4797) of the patient population after the initiation of CDS. There was a small but significant increase in the mean patient age after CDS implementation (P = .0002375; age before = 58.26 ± 18.5 vs after = 59.15 ± 18.2 years). However, this minor average increase (less than 1 year) is unlikely to account for decreased plasma utilization during the intervention period. While the rate of use of plasma at most recent INR of 1.7 or less was decreasing at the hospital level, subanalysis of our heaviest use service lines showed mixed results. Medicine and cardiothoracic surgery showed more conservative usage as © American Society for Clinical Pathology AJCP / Original article units transfused at an INR of 1.7 or less decreased after the alert intervention from 48% to 32% (P = .0001; OR, 0.40; 95% CI, 0.34-0.48) and 55% to 45%, respectively (P < .009; OR, 0.68; 95% CI, 0.51-0.91). Anesthesia and general surgery actually showed the opposite trend as units transfused at an INR of 1.7 or less increased from 37% to 53% (P = .0002; OR, 1.96; 95% CI, 1.37-2.79) and 38% to 47% (P = .02; OR, 1.57; 95% CI, 1.07-2.0), respectively. About 25% of medicine plasma use occurred in the ICU setting compared with 61% for general surgery, 78% for cardiothoracic surgery, and 90% for anesthesia.
The alert fired 560 times in the intervention period out of approximately 1,396 plasma transfusions (alert to order ratio of 40%). Alert fire to plasma order ratio differed vastly between service lines ❚Figure 3❚. Cardiothoracic surgery and medicine had low alert to order ratios, 10% and 15%, respectively, while general surgery and anesthesia had high alerts ratios, 28% and 53%, respectively. In terms of behavior, the providers accepted the recommended action to remove the plasma order 33% of the time while choosing a clinical exception in the remaining two-thirds of cases (active bleeding, 31%; other clinical indication, 33%; and apheresis, 2%). Provider behavior to alerts varied significantly between service lines as well with medicine and cardiothoracic surgery removing the plasma order in response to the alert 41% and 56% of the time, respectively, while anesthesia and general surgery showed lower numbers, 25% and 9%, respectively.
Discussion
As the cost structure in the US health care system undergoes rapid change, a renewed focus among the transfusion medicine and blood bank fields has been on curtailing unnecessary blood product usage and moving beyond RBC utilization. 14, 15 Significant plasma use occurs as a prophylaxis to prevent bleeding in preoperative patients or critical care patients with minimally elevated INR (<2.0). 16 Additional significant use occurs in patients with perioperative bleeding and lack of coagulopathy or coagulopathy without clinical evidence of bleeding. A review of plasma use in UK ICUs showed that 31% of plasma treatments were given to patients without prothrombin time (PT) prolongation and 41% to patients without documented clinical bleeding and mildly deranged INR (<2.5). 17 A prospective audit based on the Canadian Medical Association transfusion recommendations found that 45% of plasma transfusions occurred inappropriately 18 ; this inappropriate practice included transfusion in patients with INR or PT less than 1.5 times normal (53%), transfusion for coagulopathy without bleeding (21%), and active bleeding with normal coagulation profile (11%). All these practices are inappropriate as patients with minimally elevated INR (≤2.0) have the same bleeding risks as patients with normal INR across a wide variety of procedures. 16, 19, 20 Furthermore, when INR is minimally elevated, plasma transfusion has a minimal impact in lowering INR and fails to correct it to normal in more than 99% of patients. 21, 22 The inappropriate transfusion of plasma not only leads to higher cost but also can expose patients to serious complications such as volume overload, transfusion-related acute lung injury, and delay in necessary procedures, 23 each of which can lead to worse patient outcomes.
Some institutions have established hospital guidelines to promote appropriate practices, including recommending plasma transfusion for bleeding or preoperative patients only for INR of 2 or more and for nonbleeding/ nonprocedural patients only when INR is 6 or more. 13 Other systems have implemented active approaches to have hospital laboratory and pathology medical staff discuss orders flagged as inappropriate in real time. 15, 24 These approaches have been highly successful but require intensive human labor input and delay the flow of ordering. A recent publication showed that the logic behind flagging inappropriate plasma orders based on recent INR can effectively be programmed into the EHR at the time of ordering. 14 The study found that after implementation of an adaptive alerting system, the number of plasma orders generating alerts decreased and the number of alerts associated with cancelled orders increased. However, the study ❚Figure 2❚ Percentage of fresh-frozen plasma units transfused at most recent international normalized ratio of 1.7 or less, control vs intervention period by overall hospital and high-use service lines. Control period was established for 7 months prior to go-live with the subsequent 4 months serving as the intervention period.
did not expound upon differences in absolute or relative plasma use per patient volume or changes in use at mildly elevated INR.
In our study, we implemented a well-designed BPA that carefully excluded massive transfusion orders and orders in operative and apheresis settings and automatically removed the plasma order upon acceptance. These build elements are novel for CDS design and help increase positive predictive value in alerting and adherence to recommendations. While the CDS was implemented only in nonoperative areas, it highlighted the importance of surgeons and anesthesia in making transfusion decisions in the perioperative and ICU settings. We saw a decrease in use per patient volume of 17.4%. In addition, there was a relative decrease of 12.6% in transfusion of units at an INR of 1.7 or less. The changes in use were very different between our high-use service lines such that general medicine and cardiothoracic surgery showed declines in use at mildly elevated INR similar to the entire hospital, while anesthesia and general surgery actually showed increased use. It is undetermined why anesthesia and general surgery accept rates were lower as individual chart review would be tedious and beyond the scope of this analysis. It could be that these two service lines took care of more bleeding-prone patients in the intensive care setting or were less amenable to decision support as cardiothoracic surgery did show improved usage.
Overall, we had a high alert to order ratio where about one out of three plasma orders generated an alert; this also differed significantly between service lines from 10% to 53%. Overall, the alert recommendation to remove the plasma order was followed one-third of the time, with vast differences between service lines (9%-56%). Service lines with lower acceptance of the alert recommendations chose active bleeding as an exception at a much higher rate. The service lines that had low alert to order ratios and increased adherence to alert recommendation (medicine, cardiothoracic surgery) showed improved usage patterns at an INR of 1.7 or less. These changes occurred with the intervention, with no clinically significant change in underlying patient demographics. While the provider mix at the hospital has had no major changes, one limitation to our analysis is an absence of potential provider factors (such as median number of years of experience, age, sex mix) that could have confounded changes observed seen in plasma utilization.
It is interesting to note that clinical exceptions to the alert recommendation were chosen about twice as often as the actual recommendation, with active bleeding and other clinical indication each chosen about as often as removing the order. When other clinical indication was selected, a comment was listed only 4% of the time and generally indicated that the patient was preprocedure. This brings up additional study points in the future to track if patients in whom active bleeding was selected did in fact have significant hemodynamic alterations in terms of blood pressure changes and/or hemoglobin changes. Second, in orders where "other clinical indication" was selected in the BPA, it would be important to study if there are two to three dominant uses that providers intend for plasma. Analysis within the adaptive alert system showed a mixed variety of potential scenarios when "other" was chosen. Our current alert analytics tool omits patientlevel data, preventing such an analysis, since its intended purpose is operational for a wide variety of stakeholders to access efficiently without many barriers.
A systemic review has found four factors that lead to effectiveness of CDS. Among these, providing decision support at the time and location of decision making (ie, at time of order entry) and automatic provision of support as part of the workflow (ie, automatically within the EHR vs referring to external site, etc) have the highest adjusted OR leading to success, 15 and 112, respectively. 25 As part of good CDS design, appropriate targeting is important to avoid alert fatigue, false positives, and a mind-set that a particular CDS is of low value. Our CDS build also adheres by the five "rights" of CDS, where it aims to deliver not only the right recommendation but also to only the right individual. 26 As such, the alert was built with appropriate exclusions that it would never appear on patients undergoing massive transfusion or within the operative or apheresis settings. It is also important to consider the impact that education prior to intervention and concurrently has on the effectiveness of alerts in terms of both outcome and clinical engagement. 27 Another venue beyond alerts are dashboards that can help highlight adherence to institutional guidelines per service line or per individual user compared with the median. 6 Limitations of our study include a single institutional experience. An additional limitation that we will be working on in the future will include how to exclude transfusion in patients with significant bleeding beyond the exclusions of orders as part of massive transfusions or within operative settings. As one can imagine in critically ill and bleeding patients, transfusions are often done in the ICU and other inpatient settings as part of general orders and order sets. In this experience, services that showed lower acceptance to alert recommendations did in fact chose acute bleeding as a clinical exception at a higher rate within the alert.
Conclusion
To change practice long term, decision support may be a necessary but not in itself a sufficient tool. Many providers routinely dismiss alert recommendations. Beyond the real-time CDS in this study that has had a 12% to 20% reduction in potential inappropriate plasma, a cycle of audit and feedback may augment for continuous improvement. We are in the midst of building out simple dashboards that can be delivered on a monthly basis electronically to service line chief/chairs and hospital leaders. This dashboard aims to illustrate potential inappropriate use by service lines and individual providers (% RBCs transfused with most recent hemoglobin ≥10, % plasma transfusion with most recent INR ≤2.0). This may help easily identify outliers and practice variation between service lines and individual providers within a service line.
